Literature DB >> 23531213

Murabutide revisited: a review of its pleiotropic biological effects.

Žiga Jakopin1.   

Abstract

Despite the great efforts put into their development, the list of clinically approved immunological adjuvants is still very short. Evolution of the knowledge of the immune system has enabled for rational design of novel adjuvants and has led to the conclusion that more than one type of adjuvant will be required. Derivatives of muramyl dipeptide (MDP), the minimal immunomodulatory structure of bacterial cell wall peptidoglycan, have gained considerable attention in the past decades, because of their potent adjuvant effects. Murabutide is a safe derivative of MDP, which interacts with cells of the immune system, both innate and adaptive, and exerts its effect through activation of Nod2. The transcriptional response of murabutide-stimulated macrophages revealed enhanced expression of genes coding for various proteins such as immune mediators and their receptors, transcription factors and kinases, ion channels/transporters and proteins involved in cell metabolic activity, thus reflecting a broad spectrum of biological effects. In addition to its well recognized adjuvant effect, murabutide has also been shown to enhance the host's resistance against microbial infections, nonspecific resistance against tumors and the induction of cytokines and chemokines implicated in enhancing the immune response and hematopoesis. This article provides an insight into the mechanism of action of murabutide and its interactions with the cells of the immune system in vitro and in vivo. On account of its numerous biological effects, murabutide has been the subject of several clinical studies. Many of these have confirmed its potential to synergize with cytokines of therapeutic interest in potentiating the tumoricidal activity of macrophages or targeting chronic viral diseases, as well as reducing the cytokine dosage needed to achieve a therapeutic effect. This review covers the findings of all relevant studies and focuses on the role of murabutide and its potential in the treatment of several microbial diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23531213     DOI: 10.2174/0929867311320160002

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  8 in total

1.  Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.

Authors:  Naihan Chen; Monica M Johnson; Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2018-02-02       Impact factor: 9.776

Review 2.  Drug delivery for the treatment of endometriosis and uterine fibroids.

Authors:  David R Friend
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

3.  Different effects of the immunomodulatory drug GMDP immobilized onto aminopropyl modified and unmodified mesoporous silica nanoparticles upon peritoneal macrophages of women with endometriosis.

Authors:  Yuliya Antsiferova; Nataliya Sotnikova; Elena Parfenyuk
Journal:  Biomed Res Int       Date:  2013-12-24       Impact factor: 3.411

Review 4.  Role of Muramyl Dipeptide in Lipopolysaccharide-Mediated Biological Activity and Osteoclast Activity.

Authors:  Hideki Kitaura; Masahiko Ishida; Keisuke Kimura; Haruki Sugisawa; Akiko Kishikawa; Kazuhiro Shima; Saika Ogawa; Jiawei Qi; Wei-Ren Shen
Journal:  Anal Cell Pathol (Amst)       Date:  2018-02-14       Impact factor: 2.916

Review 5.  Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.

Authors:  Sanja Nabergoj; Irena Mlinarič-Raščan; Žiga Jakopin
Journal:  Med Res Rev       Date:  2018-12-13       Impact factor: 12.944

Review 6.  Translation of peptidoglycan metabolites into immunotherapeutics.

Authors:  Matthew E Griffin; Charles W Hespen; Yen-Chih Wang; Howard C Hang
Journal:  Clin Transl Immunology       Date:  2019-11-29

Review 7.  Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency.

Authors:  Eliza Iwicka; Justyna Hajtuch; Krystyna Dzierzbicka; Iwona Inkielewicz-Stepniak
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

Review 8.  An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery.

Authors:  Kailash C Petkar; Suyash M Patil; Sandip S Chavhan; Kan Kaneko; Krutika K Sawant; Nitesh K Kunda; Imran Y Saleem
Journal:  Pharmaceutics       Date:  2021-03-27       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.